logo
Lawmakers try to tackle the mental and emotional effects of wildfires

Lawmakers try to tackle the mental and emotional effects of wildfires

Yahoo21-02-2025
Insurance providers in California would be required to reimburse patients who seek mental health care after a natural disaster under proposed legislation to address the emotional and mental trauma of wildfire victims.
The Eaton and Palisades fires starting on Jan. 7 burned through large swaths of Los Angeles County, destroying over 11,000 buildings, resulting in 29 deaths and around $30 billion in property damage. Experts and legislators anticipate that the devastation will likely leave lasting emotional and physical scars on residents whose lives were upended by the tragedies.
"As Angelenos continue to recover from the devastating firestorms, the Assembly is moving quickly to help and support residents, including with assistance for mental and behavioral health,' said Assembly Speaker Robert Rivas (D-Hollister)
Assembly Bill 1032, authored by Assemblymember John Harabedian (D-Los Angeles) and supported by Rivas, would require healthcare service plans and insurers to reimburse eligible enrollees for up to 12 annual visits with a licensed behavioral health provider if they live in a county affected by a wildfire-related local or state emergency.
Read more: Opinion: The reported costs of the Los Angeles fires are staggering. The hidden costs are worse
Harabedian said that legislators have put all of their focus on the 'physical rebuilding' but 'haven't prioritized the mental health short-term and long-term effects' of the wildfires.
If the bill is passed and signed into law, the benefits will begin in 2026 and will be available for up to one year after an official state of emergency is lifted.
From Jan. 7 to Jan. 15, according to Harabedian's office, the 988 Suicide & Crisis Lifeline experienced a fivefold increase in the number of calls associated with the Disaster Distress Helpline for the Los Angeles region. The predominant emotions callers reported included 'fear, grief, and a real sense of uncertainty.'
Dr. Le Ondra Clark Harvey, chief executive of the California Behavioral Health Assn. and a supporter of the bill, said the physical symptoms someone might experience during and after a natural disaster could include fatigue, headaches, muscle pain, difficulty falling asleep, brain fog, inability to concentrate and flashbacks.
Read more: L.A. opens resource centers for people who lost work in the fires
'Wildfires are not an anomaly for Southern California but the number of wildfires happening at the same time and the level of destruction was really catastrophic compared to wildfires I've seen in my lifetime,' she said. The "shock of it is more impactful" for residents in urban areas because they can be more 'caught off guard.'
Researchers, according to a 2024 study by Nature Mental Health, examined the relationship between anxiety and wildfires and found an increase in emergency room visits for anxiety disorders after wildfire events in California and other parts of the Western U.S. from 2007 to 2018.
Among the most vulnerable populations during these disasters are children and older adults, Clark Harvey said, and she emphasized the need for continuous care.
'It's important during this time people understand how to take care of themselves,' she said. 'If you're having anything out of the normal impacting your daily functioning in the wake of natural disasters do not wait, address it early.'
Sign up for Essential California for news, features and recommendations from the L.A. Times and beyond in your inbox six days a week.
This story originally appeared in Los Angeles Times.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CSL slashes 15% of workforce and offshoots vaccine division
CSL slashes 15% of workforce and offshoots vaccine division

Yahoo

time20 hours ago

  • Yahoo

CSL slashes 15% of workforce and offshoots vaccine division

Australia's largest pharmaceutical company CSL will reduce its headcount by 15% and spin off its vaccine division in response to an 'unprecedented level of challenge and volatility'. CSL expects a one-off, pre-tax restructuring cost hit of $700m-$770m in the 2026 financial year. The company has conducted a series of changes across its research & development (R&D) department, operating model, and plasma network. For example, the company closed 22 underperforming plasma centres in August 2025. CSL did not disclose the areas of the company from where the 15% reduction in employee base would be initiated. As of 2024, CSL employs 32,000 people globally. The initiatives are expected to lead to savings of $500m-$550m progressively over the next three years, with the majority achieved by the end of the 2027 financial year. CSL said it would redirect the funds to 'high priority opportunities'. While most of CSL's revenue comes from its blood plasma treatments for rare illnesses, the pharma company is also one of the world's largest influenza vaccine manufacturers. It supplies more than 130 million doses of seasonal influenza doses globally each year in its Afluria, Fluad and Flucelvax brands. CSL also announced a planned spin-off of its vaccine division, known as CSL Seqirus. The company did not disclose a valuation for the demerger, which is slated to be completed in early 2026 and produce a publicly listed company in Australia, but CEO Dr Paul McKenzie said it would help 'reshape and simplify the [core] business'. Profit in the vaccine unit dipped due to reduced demand in the US – a revenue area the company hopes to address in 2026. "We firmly believe that a simplified and focused CSL is best for patients, best for our people, and best for our shareholders,' McKenzie added. The company said it would also buy back A$750m ($486.50m) of shares this financial year, partaking in a wider trend of share buybacks across the global pharma industry. Sanofi and Eli Lilly are both undertaking billion-dollar share buyback programmes. The significant restructuring, announced on CSL's 2025 financial year earnings report, eclipsed what was a positive year for the company. Net profit after tax was $3bn for the past 12 months up to June 2025, a rise of 15% on constant currencies. CSL's headcount reduction and vaccine spinoff dragged shares down 9.5%, from A$271.32 at market close on 18 August to A$245.45 at market open on 19 August. The Australian-listed company has a market cap of A$109.1bn, making it the country's fifth-largest company. In regard to impacts from tariffs, McKenzie said CSL's strategic initiatives would not be impacted due to its heavy US manufacturing presence. His statement echoed wider sentiment shared by big pharma company execs in the Q2 earnings window, many of whom expect minimal impact. Navigate the shifting tariff landscape with real-time data and market-leading analysis. Request a free demo for GlobalData's Strategic Intelligence . "CSL slashes 15% of workforce and offshoots vaccine division" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025
argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025

Yahoo

timea day ago

  • Yahoo

argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025

August 19, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will host a webinar, titled 'R&D Spotlight | Pioneering MuSK Biology with ARGX-119' on Tuesday, September 16, 2025, at 2:00pm ET. The webinar will be the first of a 'mini' series highlighting the argenx pipeline and research and development strategy. argenx management and scientific leadership will be joined by key opinion leaders, who will discuss the development of the MuSK agonist program, ARGX-119, and its potential to treat neuromuscular diseases, including congenital myasthenic syndromes (CMS), amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). A webcast of the event can be accessed on the Investors section of the argenx website at A replay of the webcast will be available on the argenx website for approximately one year following the presentation. About argenx argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit and follow us on LinkedIn, Instagram, Facebook, and YouTube. Contacts Media: Colin McBeancmcbean@ Investors: Alexandra Royaroy@

Cynosure Lutronic Announces U.S. Clearance of the XERF™ Device, Redefining the Future
Cynosure Lutronic Announces U.S. Clearance of the XERF™ Device, Redefining the Future

Business Wire

time2 days ago

  • Business Wire

Cynosure Lutronic Announces U.S. Clearance of the XERF™ Device, Redefining the Future

WESTFORD, Mass.--(BUSINESS WIRE)--Cynosure Lutronic, a global leader in energy-based medical aesthetic devices, is proud to announce that its XERF™ system, an innovative radiofrequency (RF) technology for skin tightening, has received clearance from the U.S. Food and Drug Administration. The XERF system is a groundbreaking, non-invasive solution for skin revitalization that tightens skin without the need for numbing, needles, or downtime, and is safe for all skin types. Key Features: World's First Single Shot, Multifrequency Monopolar RF Technology: This innovation combines 6.78 MHz and 2 MHz frequencies, enabling providers to precisely deliver energy at multiple tissue depths, effectively heating the fibrous septa to generate both immediate and lasting skin tightening results. Wave Fit™ Pulse and Advanced Integrated Cryogen Delivery (ICD) Cooling Technology: These advanced technologies work in tandem to regulate energy delivery and maintain optimal surface temperature, ensuring a comfortable treatment without the need for numbing. Innovative Spider Pattern Tip: Designed to reduce skin edge effects, this unique tip ensures a controlled treatment environment, increasing treatment efficacy and patient safety. 'Securing clearance for the XERF device in the U.S. marks a major milestone for Cynosure Lutronic as we accelerate our growth across North America,' said Lowinn Kibbey, President, North America at Cynosure Lutronic. 'The U.S. market represents one of the largest and most dynamic aesthetics markets in the world, and we're proud to now offer patients and providers access to a breakthrough skin-tightening solution that delivers powerful results with a more comfortable, non-invasive experience.' 'As a fellowship-trained cosmetic dermatologist, we prioritize treatments in our clinic that can consistently deliver results with minimal risk and downtime. The XERF system incorporates the newest technology to safely deliver energy deeper down in the skin, while offering intelligent cooling for superior protection and patient comfort,' said Jordan V. Wang, MD, MBE, MBA, who is the Medical Director of Laser & Skin Surgery Center of Pennsylvania. Industry Milestone and Impact The XERF device launched in 2024 and is currently sold in Korea, Japan, Hong Kong and Canada. For more information, please visit About Cynosure Lutronic, Inc With over 30 years of combined innovation and action as the global leader in energy-based devices and superior medical aesthetic treatments, Cynosure Lutronic enables dermatologists, plastic surgeons, medical spas, and other healthcare practitioners to deliver non-invasive and minimally invasive procedures to their patients. Committed to research and development at the forefront of aesthetic technology, Cynosure Lutronic now proudly offers the most extensive portfolio of aesthetic devices in the industry, providing its customers with a more comprehensive range of solutions for skin resurfacing and revitalization, hair removal, vascular lesion treatment, skin toning, and body contouring. Cynosure Lutronic sells its products globally through a direct sales force in the United States, Canada, France, Morocco, Germany, Spain, the United Kingdom, Australia, China, Japan, and Korea, and through international distributors in approximately 130 other countries. For more information, please visit The XERF™ device is indicated for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. All instances of the term 'skin tightening' are used to describe tightening effects that occur via soft tissue coagulation. Dr. Jordan Wang is a paid consultant of Cynosure Lutronic.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store